CDMO business initiated such as mRNA vaccine raw materials peptides
10 billion KRW invested in Hanmi Fine Chemical facility expansion
SEOUL, South Korea, May 22, 2022 /PRNewswire/ — Hanmi Fine Chemical (hereinafter Hanmi FC) a subsidiary of Hanmi Pharmaceutical Group specializing in APIs(Active Pharmaceutical Ingredient) development and manufacturing, is now accelerating a new business, expanding its specialties from ongoing APIs to ‘high-tech CDMO ‘ services.
Due to the COVID-19 pandemic, there has been an increase in the global demand for high-level, synthetic bio-pharmaceutical raw materials, such as those used in mRNA vaccines, including lipid nanoparticles (LNP), nucleotides, capping materials, polyethylene glycol (PEG) derivatives, and peptides. As such, on May 23, 2022Hanmi FC (CEO Chang Young-kil) announced that it will launch its areas of business to include CDMO projects in relevant fields.